Prospective Multi-Center Observational Study to Assess Persistence, Adherence and Changes in Disease Activity in the Children Population of Juvenile Arthritis Patients Treated With Adalimumab (HUMIRA) in the Routine Clinical Settings in the Russian Federation
Phase of Trial: Phase IV
Latest Information Update: 05 Nov 2018
At a glance
- Drugs Adalimumab (Primary)
- Indications Juvenile rheumatoid arthritis
- Focus Therapeutic Use
- Acronyms PETITE
- Sponsors AbbVie
- 31 May 2018 Status changed from not yet recruiting to recruiting.
- 31 May 2018 Planned End Date changed from 31 Mar 2020 to 31 Dec 2019.
- 31 May 2018 Planned primary completion date changed from 31 Mar 2020 to 31 Dec 2019.